English
Home > Products > CAS NO 143782-23-4

China CAS NO 143782-23-4 Factory

Being a result of ours specialty and service consciousness, our corporation has won a very good status amid buyers all over the world for CAS NO 143782-23-4,143782-23-4,Enzalutamide intermediate,Enzalutamide advance intermediate,4-isothiocyanato-2-(trifluoroMethyl), Sincerely stay up for serving you from the in the vicinity of future. You are sincerely welcome to go to our company to talk company face to face with each other and create long-term co-operation with us!
CAS NO 143782-23-4, Only for accomplishing the good-quality product to meet customer's demand, all of our products have been strictly inspected before shipment. We always think about the question on the side of the customers, because you win, we win!

Related Products

Hot Products

  • (4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone

    (4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone

    Product Name:(4S)-3-[5-(4-Fluorophenyl)-1,5-dioxopenyl]-4-phenyl-2-oxazolidinone
    Molecular Formula:C20H18FNO4
    Molecular Weight:355.36
    CAS Registry Number:189028-93-1
  • Tazarotene

    Tazarotene

    Product Name:Tazarotene
    Molecular Formula:C21H21NO2S
    Molecular Weight;351.46
    CAS Registry Number;118292-40-3
  • NADH, disodium salt

    NADH, disodium salt

    Product Name:NADH, disodium salt
    Molecular Formula:C21H30N7NaO14P2
    Molecular Weight:689.44
    CAS Registry Number:606-68-8
  • 4-Chloro-4'-fluorobutyrophenone

    4-Chloro-4'-fluorobutyrophenone

    Product Name:4-Chloro-4'-fluorobutyrophenone
    Molecular Formula:C10H10ClFO
    Molecular Weight:200.64
    CAS Registry Number:3874-54-2
  • Dabigatran ethyl AcOH Salt

    Dabigatran ethyl AcOH Salt

    Product Name:Dabigatran ethyl AcOH Salt
    Molecular Formula:C27H29N7O3
    Molecular Weight:499.58
    CAS Registry Number:429658-95-7
  • 2,4-Difluorotoluene

    2,4-Difluorotoluene

    Product Name:2,4-Difluorotoluene
    Molecular Formula:C7H6F2
    Molecular Weight:128.12
    CAS Registry Number:452-76-6
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications. Our products are produced under strict procedures and cGMP (Current Good Manufacturing Practices). In addtion, we can also customize new pharmaceutical compounds for new drugs.

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept